Clinical Trial

RCT aiTriage Chest Pain Risk Stratification

Completed Phase 4
View on ClinicalTrials.gov →
Summary
Chest pain is one of the most common reasons people visit the Emergency Department (ED). While most cases are not serious, a small number may lead to life-threatening heart problems, known as Major Adverse Cardiac Events (MACE). Emergency staff need to quickly identify these high-risk patients, but current methods often take time, involve lab tests, and strain already busy EDs. In Singapore, for example, SGH sees over 120,000 ED patients a year. In the U.S., chest pain accounts for around 8-10 million ED visits annually, yet fewer than 10% are ultimately diagnosed with MACE. Still, over half of chest pain patients undergo extensive and costly testing, adding up to $10-13 billion each year. This over-testing is done to avoid missing a critical case, but it's inefficient and stressful for both staff and patients. Traditional risk scoring tools like TIMI, GRACE, HEART, and EDACS require time and blood test results, delaying early intervention. Waiting times in EDs can be 1-2 hours, during which patient conditions may worsen unnoticed. To address this, we've developed aiTriage, a portable device that uses AI to analyze heart rate variability, ECG readings, blood pressure, and oxygen levels. It provides a real-time risk score within 5 minutes, helping doctors decide which patients need urgent care. Unlike current methods, aiTriage works without waiting for lab tests and can ease the load on EDs. No existing devices offer real-time MACE risk scoring like aiTriage. Our previous studies show that this system outperforms standard tools and could transform how chest pain is managed in emergency care, saving time, money, and lives.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-10.
Status change: Recruiting → Completed 2026-01-06
Trial Details
NCT Number NCT07074808
Lead Sponsor Singapore General Hospital
Conditions Chest Pain, Emergencies
Enrollment 1,120 participants
Start Date 2022-11-11
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-01-08